In recent years, chemotherapy has played an important role in cancer treatment. However, the general population often thinks that chemotherapy can cause adverse side effects such as hair loss, vomiting, fatigue, and even death. Of course, these negative effects of chemotherapy are not only reflected in the patient's clinical manifestations, but clinicians are also increasingly concerned about the harm of chemotherapy to patients. A large body of research evidence indicates that systemic chemotherapy is at greater risk and may even threaten the lives of patients. Throughout a large number of studies, it is not difficult to find that chemotherapy is actually a double-edged sword. When used at the right time, it can greatly save the lives of patients. However, improper use often has adverse effects on patients. What are the drawbacks? What are the advantages? Xiaobian has organized the relevant research progress, shared it with everyone, and studied together! [1] 2017 AMSNMMI: Individualized therapy may significantly improve the quality of life of patients with neuroendocrine cancer English original: Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumors: initial dosimetry and safety results of the P-PRRT trial. At the 2017 annual meeting of the American Society of Nuclear Medicine and Molecular Imaging, researchers from Laval University said that neuroendocrine cancer is a very difficult and incurable cancer, but by individualizing the dose of peptide receptors in patients. Radionuclide therapy (PRRT) may be able to slow the progression of the patient's body tumors and improve patient survival. PRRT is a relatively rare treatment that is very easy to ignore neuroendocrine tumors (NETs), and researchers hope to develop targeted therapies to adsorb peptide-positive tumors while still retaining systemic therapy damage. Collective organization. Jean-Mathieu Beauregard, MD, said that by now, most PRRT therapies have adopted a one-size-fits-all approach, which means that each patient receives the same amount of radioactive material, which ultimately leads to body organ and Tumors absorb highly variable radiation doses, and many patients do not benefit from this therapy because they terminate the treatment of small radiation doses compared to the body's ability to withstand. [2] The Lancet Oncol: New chemotherapy methods can significantly improve the quality of life of patients with breast cancer Doi:10.1016/S1470-2045(17)30404-7 Recently, a study published in the international magazine The Lancet Oncology, researchers from the London Cancer Institute found that the chemotherapy drug capecitabine can significantly improve the quality of life of cancer patients, and it also serves as a A new alternative strategy (replacement of the CMF strategy) to help inhibit breast cancer recurrence (after administration of the drug to the table of treatment). The researchers said that after surgery, about 4,400 clinical trial patients began to use the chemotherapy drug epirubicin after following capecitabine therapy. They found that the drug capecitabine can make patients experience less. Side effects, but also improve the quality of life of patients. Regardless of the treatment, patients experience some side effects, but patients undergoing CMF therapy often experience fewer side effects, including early menopause, nausea, infection, thrombosis, and anemia. During clinical trials, patients are often followed for 12, 18, and 24 months, followed by a 10-year follow-up survey. The goal of the investigator is to see if the patient's body cancer recurs and monitor the patient's side effects. Over 8 years of patients have not experienced a recurrence of cancer for at least 5 years. [3] Do you want chemotherapy? Genetic testing is quietly changing the cancer treatment process At the end of last month, a group of British scientists used the national breast cancer and lung cancer chemotherapy data from the public health department in England to comprehensively analyze the 30-day mortality rate of patients after chemotherapy. This is the first time ever to use national data to analyze the survival of cancer after chemotherapy. Using these data, the researchers analyzed the effects of age, health, and other factors on the outcome of chemotherapy. Provides a reliable baseline "chemotherapy" for chemotherapy in UK patients. Their research results were finally published in The Lancet Cancer. In today's advocacy of " precise medical care ", it is often difficult for doctors to make clinical treatment decisions simply relying on the "baseline" of thick lines. Doctors obviously need more data to make accurate judgments and decisions. In recent years, the cost of gene sequencing has been decreasing, and more and more cancer patients are beginning to try genetic testing as an aid to cancer diagnosis. With the continuous accumulation of genetic testing data, the role of genetic testing results in cancer treatment decision-making has gradually emerged. [4] Nature: Significant progress has been made in the development of melanoma individualized therapy! Doi:10.1038/nature22079 Although immunotherapy based on programmed cell death 1 receptor protein (PD-1) can successfully treat metastatic melanoma patients, more than half of patients do not receive long-term treatment by seeing tumor shrinkage. Benefits, one of the possibilities is that the drugs do not play their due role in the body of these patients. These PD-1 blocking drugs lack a biological effect in many patients' bodies; however, a recent publication in In a study published in the international journal Nature, researchers from institutions such as the University of Pennsylvania have shown that, in fact, about 80% of patients have an increased number of T cells that respond to these therapies, PD-1 targeting antibody pembrolizumab It is a checkpoint inhibitor drug that is effective in inhibiting the PD-1 receptor and thereby promotes T cell replication and strongly reacts to cancer cells. But why is there a certain disconnect between promoting tumor shrinkage and increasing the number of T cells in the patient's body? In this study, the researchers gave some clues; Professor E. John Wherry pointed out that we found that the size of the tumor before treatment in the patient's body can determine the T cell response to the drug to inhibit the tumor strength of the patient, tumor The larger the size, the stronger the activation of T cells activated by drugs. The clinical failure experienced by many patients is not only because the body's immune system cannot be activated, but also because of the intensity of T cell reactivation and the original tumor burden of the body. Caused by imbalance. [5] The new treatment of Blood is better than standard chemotherapy, leukemia treatment or welcome to turn! DOI: 10.1182/blood-2016-05-718171 Researchers from the Australian National University (AUN) are developing a new treatment for malignant leukemia that is superior to standard chemotherapy. Dr. Nadine Hein, Principal Investigator from AUN John Curtin School of Medicine, explained that they have successfully treated mice with highly malignant acute myeloid leukemia (AML) with this new therapy. "We not only reduce the number of cancer cells, but also reduce the number of cancer stem cells, which are highly resistant to chemotherapy, and they are also the leading cause of cancer recurrence in cancer patients," Dr. Hein said. Dr. Hein explained that they used a compound called CX-5461 to target the protein production process of cancer cells. “We are testing a new treatment that will improve existing chemotherapy and improve patient outcomes,†Dr. Hein said. About 1,000 people are diagnosed with AML each year in Australia. Although mortality is age-related, the average mortality rate is as high as 70%, and only 30% of people can survive for a long time. Organic Garlic Granules,Organic Granulated Garlic,Garlic Powder To Minced Garlic,Bulk Granulated Garlic Powder shandong changrong international trade co.,ltd. , https://www.cragriculture.com
